Cite

HARVARD Citation

    Wright, K. et al. (n.d.). LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY. Neuro-oncology. 20 (2), p. i110. [Online]. 
  
Back to record